SS
ESPR

Simplicity Solutions’s Esperion Therapeutics ESPR Stock Holding History

Simplicity Solutions’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$73K Sell
24,398
-6,104
-20% -$7.92K ﹤0.01% 1027
2023
Q3 		$29.9K Buy
+30,502
New +$44.1K ﹤0.01% 974
2023
Q2 		– Sell
-11,092
Closed -$17.6K – 1096
2023
Q1 		$17.6K Buy
+11,092
New +$57.3K ﹤0.01% 1146

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Simplicity Solutions's ESPR Position: Q4 2023 in Review

Simplicity Solutions reduced its Esperion Therapeutics (ESPR) stake by 20% in Q4 2023, selling an estimated $7.92K and leaving 24,398 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Simplicity Solutions first reported a position in ESPR in Q1 2023 and has held it in 3 quarters since. 132 funds tracked by Wall St. Rank hold ESPR as of Q4 2023.

  • Simplicity Solutions held 24,398 shares of Esperion Therapeutics worth $73K as of Q4 2023.
  • Simplicity Solutions sold 6,104 Esperion Therapeutics shares in Q4 2023, an estimated $7.92K.
  • Esperion Therapeutics made up ﹤0.01% of Simplicity Solutions's portfolio in Q4 2023, its #1027 holding.
  • Simplicity Solutions first reported a position in Esperion Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2023.

Based on Simplicity Solutions's 13F filing for Q4 2023, filed 29 Jan 2024.